Ignite Creation Date:
2025-12-24 @ 1:13 PM
Ignite Modification Date:
2025-12-29 @ 10:14 PM
Study NCT ID:
NCT03047395
Status:
COMPLETED
Last Update Posted:
2024-12-11
First Post:
2017-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-02-27
Start Date Type:
ACTUAL
Primary Completion Date:
2023-11-29
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-11-29
Completion Date Type:
ACTUAL
First Submit Date:
2017-02-07
First Submit QC Date:
None
Study First Post Date:
2017-02-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2024-11-19
Results First Submit QC Date:
None
Results First Post Date:
2024-12-11
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-19
Last Update Post Date:
2024-12-11
Last Update Post Date Type:
ACTUAL